Corcept Therapeutics Incorporated — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial statements are unaudited. Corcept is a commercial-stage pharmaceutical company whose marketed product is Korlym for certain patients with Cushing’s syndrome, alongside a pipeline of cortisol-modulating drug candidates.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net product revenue | $146.8 million | $105.7 million |
| Cost of sales | $2.5 million | $1.4 million |
| Research and development | $58.5 million | $40.9 million |
| Selling, general and administrative | $56.3 million | $48.6 million |
| Operating income | $29.5 million | $14.9 million |
| Net income | $27.8 million | $15.9 million |
| Diluted EPS | $0.25 | $0.14 |
| Operating cash flow | $23.8 million | $26.0 million |
Revenue increased approximately 39%. Management attributed 67.6% of the increase to higher sales volume, with the balance primarily due to a price increase effective January 1, 2024. Approximate operating margin rose to 20.1% from 14.1%; cost of sales was 1.7% of revenue versus 1.3%.
R&D expense increased approximately 43%, primarily reflecting advancement and completion of development programs; oncology spending rose to $17.7 million from $7.3 million. SG&A increased approximately 16%, reflecting employee compensation and sales and marketing activity. Cost of sales included a one-time $0.5 million API write-off.
At March 31, 2024, cash and cash equivalents were $149.8 million and marketable securities totaled $301.3 million, for combined cash, cash equivalents and securities of $451.0 million. Total assets were $655.9 million, total liabilities $108.1 million, and stockholders’ equity $547.9 million. The filing reports no borrowings or debt balance. Operating cash flow was below net income, in part because trade receivables increased by $20.4 million. Cash and securities rose from $425.4 million at December 31, 2023.
Material developments, outlook and risks
- Korlym competition and patent dispute: Teva launched a generic Korlym product in January 2024. A district court ruled in December 2023 that Teva’s product would not infringe the asserted patents; Corcept appealed. The filing warns that generic competition could materially reduce revenue and profits. Settlements permit Sun and Hikma to enter following Teva’s launch, subject to specified conditions.
- Pipeline: In April 2024, Corcept announced preliminary open-label GRACE Phase 3 results for relacorilant in Cushing’s syndrome, reporting clinically meaningful and statistically significant improvements in specified measures and that the drug was well tolerated. These were preliminary results, not final trial outcomes. GRADIENT enrollment was complete; ROSELLA ovarian-cancer Phase 3 enrollment was complete; DAZALS enrollment was complete. The MONARCH Phase 2b miricorilant trial was initiated in October 2023.
- Expense outlook: Management expects R&D and SG&A expenses to be higher in 2024 than in 2023 as clinical programs and commercial, administrative and marketing activities advance. The filing provides no clear numerical revenue or earnings guidance in the supplied text.
- Liquidity: Management expects existing resources and operations to fund planned operations and R&D for the next 12 months and beyond without additional financing, based on current plans and expectations.
- Capital returns: A January 2024 authorization allows up to $200 million of share repurchases. Approximately $0.5 million was repurchased in Q1; about $199.5 million remained authorized at quarter-end.
- Litigation and investigation: The $14.0 million Melucci settlement was paid into escrow and reimbursed in full by insurers; final court approval was pending, with a hearing scheduled for June 6, 2024. Separately, the U.S. Attorney’s Office for the District of New Jersey is investigating matters involving Korlym sales, promotion, healthcare-professional relationships and reimbursement. The government has said Corcept is not currently a defendant but that its conduct is within the investigation’s scope. Corcept is cooperating.
- Other notable commitments and risks: A six-year sublease for a new headquarters is expected to begin around July 1, 2024; average annual base rent is $1.4 million plus $0.2 million for shared amenities. Corcept also identifies IRA-related reimbursement and manufacturer-cost changes, dependence on Korlym and a single specialty pharmacy, reliance on a single Korlym API manufacturer, and clinical-development and regulatory uncertainty as material risks.
Most important facts for investors to verify
- How Teva’s generic launch and Corcept’s patent appeal affect Korlym sales, pricing and market access.
- Whether revenue growth and receivables collection remain strong, and how rebates and payer mix affect net revenue.
- Final results and regulatory implications of GRACE, plus progress and outcomes for other late-stage trials.
- Whether R&D and SG&A spending, cash generation and the repurchase program remain consistent with management’s stated liquidity expectations.
- Final approval and disbursement of the Melucci settlement, and any material developments in the NJ USAO investigation or derivative litigation.